Cord blood cell therapy trial suspended

Article Abstract:

Umbilical cord blood stem cell therapies used in the treatment of blood cancers are forging ahead, however, suspension of a phase 1/2 trial of a non-matched cord blood therapy by Viacell following adverse events has shaken investors confidence. This has forced major investors to reevaluate the risks associated with their therapeutic strategy and increasing scrutiny on other pharmaceutical firms.

Financial management, Company investment, Investments, Fetal blood, Cellular therapy, Cell therapy

---

It came from beneath the sea

Article Abstract:

Pelagibacter ubique, is a member of a bacterial grouping called SAR 11, so called because of its discovery in the Sargasso Sea that is the most prevalent life form in the marine environment. The first member of the SAR 11 clade to be successfully cultured, Pelagibacter ubique has a genome that, despite its small size, encodes the genes necessary for the biosynthesis of all 20 amino acids.

Discovery and exploration, Bacteria, Sargasso Sea, Microbial genetics

---

Pharma consolidates its grip on post-antibody landscape

Article Abstract:

The pharma industries are switching rapidly to the use and development of fully human antibodies and their fragments as these offer numerous advantages in terms of delivery routes and manufacturing and are highly stable molecules with low molecular weight. The antibody development strategies and achievements of a number of famous pharma companies are discussed in the article.

Product development, Forecasts, trends, outlooks, Pharmaceutical preparations, Usage, Pharmaceutical industry, Forecasts and trends, Market trend/market analysis, Viral antibodies, Antibodies

Similar abstracts:

• Abstracts: Possible LCS, international sales: BAE eyes expanded markets for ship protection gun. Exec: Boeing worries about homeland security tech liability
• Abstracts: Auspicious antigens. Immunotherapy dispenses with tumor antigens. Immunosuppressive networks in the tumor environment and their therapeutic relevance
• Abstracts: Empowering the inventor: The case of monoclonal antibodies. Flexibility: The guiding principle for antibody manufacturing
• Abstracts: Recombinant protein therapeutics - success rates, market trends and values to 2010. Monoclonal antibodies in the clinic
• Abstracts: Publicity and the regulator: Striking a balance. Mind the cap. E&Y faces Equitable grilling

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.